Center-Authored Papers

Filters: Author is Antin, Joseph H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J et al..  2012.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.. Blood. 119(1):296-307. Abstract
Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers MED, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M et al..  2011.  Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.. Blood. 117(24):6714-20. Abstract
Lindsley CR, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu Z-H, Spellman SR, Lee SJ et al..  2017.  Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.. The New England journal of medicine. 376(6):536-547. Abstract
Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ et al..  2014.  Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.. Blood. 124(22):3221-7;quiz3335. Abstract
Ringdén O, Pavletic SZ, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C et al..  2009.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.. Blood. 113(13):3110-8. Abstract
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB et al..  2010.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(7):1005-17. Abstract
Unrelated Donors
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J et al..  2012.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.. Blood. 119(1):296-307. Abstract
Treatment Outcome
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB et al..  2010.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(7):1005-17. Abstract
Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ.  2008.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(2):197-207. Abstract
Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C et al..  2009.  HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(10):1644-52. Abstract
Treatment Failure
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
Transplantation, Homologous
Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong C-H, Wang H, Chin A et al..  2013.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.. The New England journal of medicine. 369(6):529-39. Abstract
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J et al..  2012.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.. Blood. 119(1):296-307. Abstract
Lindsley CR, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu Z-H, Spellman SR, Lee SJ et al..  2017.  Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.. The New England journal of medicine. 376(6):536-547. Abstract
Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ.  2008.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(2):197-207. Abstract
Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H et al..  2009.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.. JAMA : the journal of the American Medical Association. 301(22):2349-61. Abstract
Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn J-Y, Cervantes F, Copelan E et al..  2009.  Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(11):1475-8. Abstract
Transplantation Conditioning
Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ et al..  2014.  Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.. Blood. 124(22):3221-7;quiz3335. Abstract
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J et al..  2012.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.. Blood. 119(1):296-307. Abstract
Lindsley CR, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu Z-H, Spellman SR, Lee SJ et al..  2017.  Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.. The New England journal of medicine. 376(6):536-547. Abstract
Tissue Donors
Ringdén O, Pavletic SZ, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C et al..  2009.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.. Blood. 113(13):3110-8. Abstract
Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C et al..  2009.  HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(10):1644-52. Abstract
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J et al..  2012.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.. Blood. 119(1):296-307. Abstract